Deformable dressing for negative pressure therapy

JP2023551973A5Active Publication Date: 2024-11-26KCI MFG UNLIMITED CO
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
JP2023534123
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2020-12-07
Filing Date
2021-11-16
Publication Date
2024-11-26
Estimated Expiration
2041-11-16

AI Technical Summary

Technical Problem

Existing negative pressure therapy systems lack dressings that provide optimal contact and conformability to tissue sites, limiting the effectiveness of microstrains and fluid management for enhanced wound healing.

Method used

Dressings with increased deflection and conformability, achieved through a thermoforming process, featuring a polymeric film with fluid restrictions and a manifold layer, enhance contact with tissue sites, improving microstrains and fluid management.

Benefits of technology

The dressings with increased deflection and conformability improve the effectiveness of negative pressure therapy by inducing microstrains across the tissue site, enhancing wound healing through better contact and fluid management.

✦ Generated by Eureka AI based on patent content.
Patent Text Reader

Abstract

A dressing for treating a tissue site using negative pressure may have both a first non-planar surface and a second non-planar surface opposite the first non-planar surface in a relaxed state in which no external force is applied to the dressing. The dressing may include a fluid management layer including a polymer film and a plurality of fluid restriction portions extending through the polymer film and configured to deform. The dressing may also include a manifold layer coupled to the fluid management layer.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] (Cross - Reference to Related Applications) This application claims the benefit of priority of U.S. Patent Provisional Application No. 63 / 122,380, filed on December 7, 2020, which is hereby incorporated by reference in its entirety.

[0002] The present invention as claimed in the appended claims relates generally to tissue treatment systems, and more particularly, but not limited to, dressings and systems for tissue treatment using negative pressure, and methods of using dressings for tissue treatment using negative pressure.

Background Art

[0003] Clinical research and clinical practice have shown that reducing the pressure in the vicinity of a tissue site can enhance and accelerate the growth of new tissue at the tissue site. Although there are many uses for this phenomenon, it has been found to be particularly advantageous for treating wounds. Regardless of the cause of the wound, whether due to trauma, surgery, or another cause, appropriate care of the wound is important for the outcome. The treatment of wounds or other tissues by reducing pressure can generally be referred to as "negative pressure therapy", but is also known by other names including, for example, "negative pressure wound therapy", "reduced pressure therapy", "vacuum therapy", "vacuum - assisted closure", and "local negative pressure therapy". Negative pressure treatment can provide many benefits including, among other things, the migration of epithelial and subcutaneous tissues, improved blood flow, and micro - deformation of tissues at the wound site. These benefits can collectively increase the development of granulation tissue and reduce the healing time.

[0004] It is widely accepted that cleaning a tissue site can be very beneficial for the growth of new tissue. For example, wounds or cavities can be washed with therapeutic fluid solutions. These actions are generally referred to as "irrigation" and "lavage," respectively. "Dripping" is another action that generally refers to the process of slowly introducing a fluid into a tissue site, leaving the fluid in for a specified period, and then removing the fluid. For example, dripping a topical therapeutic solution onto a wound bed, when combined with negative pressure therapy, can further promote wound healing by agitating soluble contaminants in the wound bed and removing infectious material. As a result, the soluble bacterial load may be reduced, contaminants may be removed, and the wound may be cleansed.

[0005] While the clinical benefits of negative pressure therapy and / or intravenous infusion therapy are widely known, improvements to the treatment system, components, and processes can benefit both healthcare providers and patients. [Overview of the project]

[0006] Novel and useful systems, apparatus, and methods for treating tissue in a negative pressure therapy environment are described in the appended claims. Exemplary embodiments are also provided to enable those skilled in the art to fabricate and use the claimed subject matter.

[0007] In some embodiments, dressings characterized by reduced tensile strength, increased flexure, and / or improved conformity to the tissue site may be advantageously employed when providing negative pressure therapy. For example, increased flexure and / or improved conformity of the dressing may provide better contact between the tissue site and the tissue site-facing surface of the dressing. Improved contact between the dressing and the tissue site may have the effect of inducing microstrains substantially across the entire tissue site, thereby causing strain on cells throughout the tissue site and improving the outcome of negative pressure therapy.

[0008] In some embodiments, the dressing may be characterized as exhibiting increased deflection after and / or as a result of the thermoforming process. For example, the dressing may be characterized as exhibiting increased deflection compared to an otherwise similar non-thermoformed dressing.

[0009] Additionally or alternatively, in some embodiments, the dressing may be characterized as exhibiting improved fit to the tissue site after and / or as a result of the thermoforming process. For example, the dressing may be characterized as showing improved fit to the tissue site compared to an otherwise similar non-thermoformed dressing.

[0010] For example, in some embodiments, a dressing for treating a tissue site using negative pressure may have both a first non-planar surface and a second non-planar surface opposite the first non-planar surface when the dressing is relaxed and no external force is applied to it. The dressing may also include a fluid management layer comprising a polymer film and a plurality of fluid limiting portions extending through the polymer film and configured to deform. The dressing may also include a manifold layer coupled to the fluid management layer.

[0011] Another method, for example, is to form a dressing for treating a tissue site using negative pressure. The dressing formed by this method may include a fluid control layer comprising a polymer film and a plurality of fluid limiting sections extending through the polymer film and configured to deform. The dressing formed by this method may also include a manifold layer coupled to the fluid control layer. This method may include heating the fluid control layer and the manifold layer, and fitting the fluid control layer and the manifold layer to a mold while they are being heated. This method may also apply both a first non-planar surface and a second non-planar surface opposite the first non-planar surface to the dressing in a relaxed state where no external force is applied to the dressing.

[0012] Furthermore, for example, a system for treating a tissue site may include a dressing for treating the tissue site using negative pressure. The dressing may have both a first non-planar surface and a second non-planar surface opposite the first non-planar surface when in a relaxed state where no external force is applied to the dressing. The dressing may include a fluid management layer comprising a polymer film and a plurality of fluid limiting sections configured to extend through the polymer film and be deformable, and a manifold layer coupled to the fluid management layer. The system may also include a negative pressure source configured to be fluidly coupled to the dressing.

[0013] Furthermore, for example, a dressing for treating a tissue site using negative pressure may comprise a fluid control layer comprising a polymer film and a plurality of fluid limiting sections extending through the polymer film and configured to deform. The dressing may also comprise a manifold layer coupled to the fluid control layer. The dressing may be formed by a thermoforming process comprising heating the fluid control layer and the manifold layer, and conforming the fluid control layer and the manifold layer to a mold while they are being heated. At least a portion of the dressing may exhibit a decrease in tensile strength as a result of the thermoforming process.

[0014] Another method involves forming a dressing for treating a tissue site using negative pressure. The dressing formed by this process may comprise a fluid control layer comprising a polymer film and a plurality of fluid limiting sections extending through the polymer film and configured to deform, and may further comprise a manifold layer coupled to the fluid control layer. The method may include heating the fluid control layer and the manifold layer, and fitting the fluid control layer and the manifold layer to a mold while they are being heated. At least a portion of the dressing may exhibit a decrease in tensile strength as a result of the thermoforming process.

[0015] Furthermore, for example, a system for treating a tissue site may include a dressing. The dressing may include a fluid control layer comprising a polymer film and a plurality of fluid limiting sections configured to extend through the polymer film and be deformable, and a manifold layer coupled to the fluid control layer. The dressing may be formed by a thermoforming process that includes heating the fluid control layer and the manifold layer and conforming the fluid control layer and the manifold layer to a mold while they are being heated. At least a portion of the dressing may exhibit a decrease in tensile strength as a result of the thermoforming process. The system may also include a negative pressure source configured to be fluidly coupled to the dressing.

[0016] The purpose, advantages, and preferred modes of fabricating and using the claimed subject matter will be best understood by referring to the accompanying drawings in conjunction with the following detailed description of exemplary embodiments. [Brief explanation of the drawing]

[0017] [Figure 1] Figure 1 is a block diagram of an exemplary embodiment of a treatment system capable of providing negative pressure therapy and drip therapy according to this specification. [Figure 2] Figure 2 is an exploded view of an example of a dressing, showing additional details that may be relevant to some exemplary embodiments of the treatment system shown in Figure 1. [Figure 3] Figure 3 is an exploded view of an example of a dressing, showing additional details that may be relevant to some exemplary embodiments of the treatment system shown in Figure 1. [Figure 4] Figure 4 is a schematic diagram of an exemplary configuration of a layer fluid limiting section that may be relevant to several embodiments of the dressing. [Figure 5] Figure 5 is a schematic diagram of an exemplary configuration of another layer opening, showing additional details that may be relevant to several embodiments of the dressing. [Figure 6] Figure 6 is a schematic diagram of the exemplary layer in Figure 4, superimposed on the exemplary layer in Figure 5. [Figure 7]FIG. 7 is a sectional view showing additional details that may be associated with some exemplary embodiments of the dressing of FIG. 2. [Figure 8] FIG. 8 is a schematic diagram of an exemplary configuration of a manifold layer that may be associated with some embodiments of the dressing. [Figure 9] FIG. 9 is a schematic diagram of an exemplary configuration of a manifold layer that may be associated with some embodiments of the dressing. [Figure 10] FIG. 10 is a partial sectional view showing additional details that may be associated with some exemplary embodiments of the therapy system of FIG. 1. **DETAILED DESCRIPTION OF THE INVENTION**

[0018] The following description of the exemplary embodiments provides information that enables those skilled in the art to make and use the subject matter recited in the appended claims, but may omit certain details that are already well known in the art. Accordingly, the following detailed description is to be construed as illustrative and not restrictive.

[0019] FIG. 1 is a block diagram of an exemplary embodiment of a therapy system 100 according to the present specification that can provide negative pressure therapy using the dropping of a topical treatment solution to a tissue site.

[0020] As used in this context, the term "tissue site" broadly refers to a wound, defect, or other treatment target located on or within a tissue, including but not limited to bone tissue, adipose tissue, muscle tissue, nerve tissue, dermal tissue, vascular tissue, connective tissue, cartilage, tendon, or ligament. Wounds can include, for example, chronic, acute, traumatic, subacute, and lacerated wounds, partial thickness burns, ulcers (such as diabetic ulcers, pressure ulcers, or venous insufficiency ulcers), skin flaps, and transplanted tissues. The term "tissue site" can also refer to an area of tissue where there may not necessarily be a wound or defect, but instead, an area where it may be desirable to add or promote the growth of additional tissue. For example, negative pressure may be applied to a tissue site to grow additional tissue that can be harvested and transplanted.

[0021] The treatment system 100 may include a negative pressure source or negative pressure supply unit, such as a negative pressure source 105, and one or more distribution components. The distribution components are preferably detachable and may be disposable, reusable, or recyclable. A dressing, such as a dressing 110, and a fluid container, such as a container 115, are examples of distribution components that may be relevant to some embodiments of the treatment system 100. As shown in the example in Figure 1, in some embodiments the dressing 110 may include a tissue interface 120, a cover 125, or both.

[0022] Fluid conduits are another exemplary example of distribution components. In this context, “fluid conduit” broadly includes tubes, pipes, hoses, conduits, or other structures having one or more lumens or open paths adapted to transport fluid between two ends. Typically, tubes are elongated cylindrical structures with some degree of flexibility, although their geometric shape and rigidity can vary. Also, some fluid conduits may be molded within other components, or otherwise integrated integrally with other components. Distribution components may also include or have interfaces or fluid ports to facilitate the coupling and uncoupling of other components. In some embodiments, for example, a dressing interface may facilitate coupling a fluid conduit to a dressing 110. For example, such a dressing interface may be a SENSAT.RAC® Pad, available from Kinetic Concepts, Inc. (San Antonio, Texas).

[0023] The treatment system 100 may also include a regulator or controller, such as a controller 130. Additionally, the treatment system 100 may include sensors for measuring operating parameters and providing feedback signals indicating those parameters to the controller 130. For example, as shown in Figure 1, the treatment system 100 may include a first sensor 135 and a second sensor 140 coupled to the controller 130.

[0024] The treatment system 100 may also include a source of the drip solution. For example, the solution source 145 may be fluid-coupled to the dressing 110, as shown in the exemplary embodiment of Figure 1. In some embodiments, the solution source 145 may be fluid-coupled to a positive pressure source such as a positive pressure source 150, a negative pressure source such as a negative pressure source 105, or both. Regulators such as a drip regulator 155 may also be fluid-coupled to the solution source 145 and the dressing 110 to ensure an appropriate dose of the drip solution (e.g., saline) to the tissue site. For example, the drip regulator 155 may include a piston, which may be pneumatically actuated by the negative pressure source 105 to draw the drip solution from the solution source 145 during negative pressure intervals and to drip the solution onto the dressing during venting intervals. Additionally or alternatively, a controller 130 may be coupled to the negative pressure source 105, the positive pressure source 150, or both to control the dose of the drip solution to the tissue site. In some embodiments, as shown in the example in Figure 1, the drip regulator 155 may also be fluidly coupled to the negative pressure source 105 via the dressing 110.

[0025] Some components of the treatment system 100 may be housed within or used in conjunction with other components such as sensors, processing units, alarm indicators, memory, databases, software, display devices, or user interfaces that further facilitate the therapy. For example, in some embodiments, a negative pressure source 105 can be combined with a controller 130, a solution source 145, and other components to form a treatment unit.

[0026] In general, the components of the treatment system 100 may be connected directly or indirectly. For example, the negative pressure source 105 may be directly connected to the container 115, or indirectly connected to the dressing 110 via the container 115. The connection may include fluid, mechanical, thermal, electrical, or chemical (such as chemical bonding), or in some contexts, a combination of connections. For example, the negative pressure source 105 may be electrically connected to the controller 130, or fluidly connected to one or more distribution components to provide a fluid pathway to the tissue site. In some embodiments, the components may also be connected by physical proximity, by being integrated into a single structure, or by being formed from the same material piece.

[0027] The negative pressure supply unit, such as the negative pressure source 105, may be a reservoir of negative pressure air, or it may be a manual or electric device such as a vacuum pump, suction pump, wall suction port (available in many medical facilities), or micropump. "Negative pressure" generally refers to a pressure below local ambient pressure, such as the ambient pressure in the local environment outside the sealed therapeutic environment. Often, local ambient pressure can also be atmospheric pressure where the tissue site is located. Alternatively, the pressure may be below the hydrostatic pressure associated with the tissue at the tissue site. Unless otherwise indicated, the pressure values ​​described herein are gauge pressures. A reference to an increase in negative pressure typically refers to a decrease in absolute pressure, and a reference to a decrease in negative pressure typically refers to an increase in absolute pressure. The amount and nature of the negative pressure provided by the negative pressure source 105 may vary depending on the therapeutic requirements, but the pressure is generally a low vacuum, also commonly referred to as a rough vacuum, ranging from -5 mmHg (-667 Pa) to -500 mmHg (-66.7 kPa). The typical therapeutic range is between -50 mmHg (-6.7 kPa) and -300 mmHg (-39.9 kPa).

[0028] Container 115 represents a container, canister, pouch, or other storage component that may be used to manage exudate and other fluids drawn from a tissue site. In many environments, rigid containers may be preferred or required for the collection, storage, and disposal of fluids. In other environments, fluids may not be stored in rigid containers but can be properly disposed of, and reusable containers can reduce waste and costs associated with negative pressure therapy.

[0029] A controller such as controller 130 may be a microprocessor or computer programmed to operate one or more components of the treatment system 100, such as a negative pressure source 105. In some embodiments, for example, controller 130 may be a microcontroller, which generally includes an integrated circuit comprising a processor core and memory programmed to directly or indirectly control one or more operating parameters of the treatment system 100. Operating parameters may include, for example, power applied to the negative pressure source 105, pressure generated by the negative pressure source 105, or pressure distributed to the tissue interface 120. Controller 130 is also preferably configured to receive one or more input signals, such as feedback signals, and programmed to modify one or more operating parameters based on the input signals.

[0030] Sensors such as the first sensor 135 and the second sensor 140 are generally known in the art as any device capable of operating to detect or measure a physical phenomenon or characteristic, and generally provide a signal indicating the detected or measured phenomenon or characteristic. For example, the first sensor 135 and the second sensor 140 may be configured to measure one or more operating parameters of the treatment system 100. In some embodiments, the first sensor 135 may be a transducer configured to measure the pressure in an air passage and convert the measurement into a signal indicating the measured pressure. In some embodiments, for example, the first sensor 135 may be a piezoresistive strain gauge. In some embodiments, the second sensor 140 may optionally measure operating parameters of the negative pressure source 105, such as voltage or current. Preferably, the signals from the first sensor 135 and the second sensor 140 are suitable as input signals to the controller 130, but in some embodiments, some signal conditioning may be appropriate. For example, the signals may need to be filtered or amplified before they can be processed by the controller 130. Typically, a signal is an electrical signal, but it may also be represented in other forms, such as an optical signal.

[0031] The tissue interface 120 may generally be fitted to partially or completely contact the tissue site. The tissue interface 120 may take many forms and may have many sizes, shapes, or thicknesses depending on various factors such as the type of procedure being performed or the nature and size of the tissue site. For example, the size and shape of the tissue interface 120 may be fitted to the contour of a deep, irregularly shaped tissue site. Some or all of the surfaces of the tissue interface 120 may have a ridged profile, a rough profile, or a jagged profile.

[0032] In some embodiments, the tissue interface 120 may or may not include a manifold. In this context, the manifold may include means for collecting or distributing fluid to a tissue site under pressure. For example, the manifold may be adapted to receive negative pressure from a source and distribute the negative pressure through a plurality of openings, which may have the effect of collecting fluid across the tissue site and drawing the fluid towards the source. In some embodiments, the fluid path may be reversed, or a secondary fluid path may be provided to facilitate the delivery of fluid, such as fluid from a source of intravenous solution, across the tissue site.

[0033] In some exemplary embodiments, a manifold may comprise multiple pathways that can be interconnected to improve fluid distribution or collection. In some exemplary embodiments, a manifold may comprise, or be formed from, a porous material having interconnected fluid pathways. Examples of suitable porous materials that can be adapted to form interconnected fluid pathways (e.g., channels) include cellular foams, including open-cell foams such as mesh foams; porous tissue aggregates; and other porous materials such as gauze or felt mats that generally include pores, edges, and / or walls. Liquids, gels, and other foams may also comprise, or be cured to comprise, openings and fluid passages. In some embodiments, a manifold may additionally or alternatively comprise projections that form interconnected fluid pathways. For example, a manifold may be molded to have surface projections that define interconnected fluid passages.

[0034] In some embodiments, the cover 125 may provide a barrier against bacteria and protection from physical trauma. The cover 125 may also be constructed from a material that can reduce evaporation loss and provide fluid sealing between two components or two environments, such as fluid sealing between a therapeutic environment and a local external environment. The cover 125 may include, or be formed from, an elastomer film or membrane that can provide suitable sealing to maintain the negative pressure of a given negative pressure source at a tissue site. In some applications, the cover 125 may have a high moisture-vapor transmission rate (MVTR). For example, in some embodiments, the MVTR may be at least 250 grams / m² per 24 hours when measured using the upright cup method according to the ASTM E96 / E96M Upright Cup Method at 38°C and 10% relative humidity (RH). In some embodiments, an MVTR of up to 5,000 grams / m² per 24 hours may provide effective air permeability and mechanical properties.

[0035] In some exemplary embodiments, the cover 125 may be a polymer drape, such as a polyurethane film, that is permeable to water vapor but impermeable to liquids. Such drapes typically have a thickness in the range of 25 to 50 microns. For permeable materials, the permeability should generally be low enough to maintain the desired negative pressure. The cover 125 may comprise, for example, one or more of the following materials: polyurethanes (PU) such as hydrophilic polyurethane, cellulose derivatives, hydrophilic polyamides, polyvinyl alcohol, polyvinylpyrrolidone, hydrophilic acrylics, silicones such as hydrophilic silicone elastomers, natural rubber, polyisoprene, styrene-butadiene rubber, chloroprene rubber, polybutadiene, nitrile rubber, butyl rubber, ethylene propylene rubber, ethylene propylene diene monomer, chlorosulfonated polyethylene, polysulfurized rubber, ethylene vinyl acetate (EVA), copolyesters, and polyether-blocked polyamide copolymers. Such materials are commercially available, for example, Tegaderm® drapes from 3M Company (Minneapolis, Minnesota), polyurethane (PU) drapes from Avery Dennison Corporation (Pasadena, California), polyether block polyamide copolymer (PEBAX) from Arkema SA (Colombes, France), and Inspire 2301 and Inspire 2327 polyurethane films from Exopack Advanced Coatings (Wrexham, United Kingdom). In some embodiments, the cover 125 may include Inspire 2301 having an MVTR (Upright Cup Method) of 2600 g / m2 / 24 hours and a thickness of about 30 microns.

[0036] The mounting device may be used to attach the cover 125 to a mounting surface such as intact skin, a gasket, or another cover. The mounting device can take many forms. For example, the mounting device may be a medically acceptable pressure-sensitive adhesive configured to bond the cover 125 to the skin around the tissue site. In some embodiments, for example, part or all of the cover 125 may be coated with an adhesive such as an acrylic adhesive, which may have a coating weight of about 25 to 65 grams / square meter (gsm). In some embodiments, a thicker adhesive, or a combination of adhesives, may be applied to improve the seal and reduce leakage. Other exemplary embodiments of the mounting device may include double-sided tape, glue, hydrocolloid, hydrogel, silicone gel, or organogel.

[0037] Solution source 145 may also represent a container, canister, pouch, bag, or other storage component capable of providing a solution for drip therapy. The composition of the solution may vary depending on the prescribed therapy, but examples of solutions that may be suitable for some formulations include hypochlorite solutions, silver nitrate (0.5%), sulfur-based solutions, biguanides, cationic solutions, and isotonic solutions.

[0038] During operation, the tissue interface 120 may be positioned within a tissue site, on a tissue site, on a tissue site, or otherwise in close proximity to a tissue site. For example, if the tissue site is a wound, the tissue interface 120 may partially or completely cover the wound, or may be positioned on top of the wound. The cover 125 may be positioned on the tissue interface 120 and sealed to a mounting surface near the tissue site. For example, the cover 125 may be sealed to the intact epidermis surrounding the tissue site. Thus, the dressing 110 can provide a sealed therapeutic environment in close proximity to the tissue site that is substantially isolated from the external environment, and the negative pressure source 105 can reduce the pressure in that sealed therapeutic environment.

[0039] Generally, exudates and other fluids flow along a fluid path toward lower pressure. Therefore, the term “downstream” can typically refer to a location in the fluid path that is relatively closer to a negative pressure source or further away from a positive pressure source. Conversely, the term “upstream” can refer to a location that is further away from a negative pressure source or closer to a positive pressure source. Similarly, it may be convenient to describe certain features in terms of the “inlet” or “outlet” of the fluid in such a reference system. This orientation is generally assumed in this specification for the purpose of describing various features and components. However, the fluid path may also be reversed in some applications, for example, by replacing a negative pressure source with a positive pressure source.

[0040] In the sealing treatment environment, the negative pressure applied across the tissue site via the tissue interface 120 can induce large and small strains in the tissue site. The negative pressure can also remove exudate and other fluids from the tissue site, which can be collected in the container 115.

[0041] In some embodiments, the controller 130 can receive and process data from one or more sensors, such as a first sensor 135. The controller 130 can also control the operation of one or more components of the treatment system 100 to manage the pressure delivered to the tissue interface 120. In some embodiments, the controller 130 may include an input device for receiving a desired target pressure and may be programmed to process data regarding the setting and input of the target pressure applied to the tissue interface 120. In some exemplary embodiments, the target pressure may be a fixed pressure value, which is set by the operator as the desired target negative pressure for therapy at the tissue site and then provided to the controller 130 as input. The target pressure may vary depending on the tissue site, based on the type of tissue forming the tissue site, the type of injury or wound (if any), the patient's health condition, and the attending physician's preference. After selecting the desired target pressure, the controller 130 can operate the negative pressure source 105 in one or more control modes based on the target pressure and can receive feedback from one or more sensors to maintain the target pressure at the tissue interface 120.

[0042] Figure 2 is an assembled diagram of an example of the dressing 110 of Figure 1, and shows additional details that may relate to several embodiments in which the tissue interface 120 includes two or more layers. In the embodiment of Figure 2, the tissue interface 120 includes multiple layers, e.g., a first layer, a second layer, and a third layer. More specifically, in the example of Figure 2, the tissue interface 120 includes a manifold layer 205, a fluid management layer 210, and a contact layer 215. In some embodiments, the manifold layer 205 may be located adjacent to the fluid management layer 210, and the contact layer 215 may be located adjacent to the fluid management layer 210 on the opposite side from the manifold layer 205. For example, the manifold layer 205, the fluid management layer 210, and the contact layer 215 may be stacked such that the manifold layer 205 is in contact with the fluid management layer 210, and the fluid management layer 210 is in contact with both the manifold layer 205 and the contact layer 215. One or more of the manifold layer 205, the fluid management layer 210, and the contact layer 215 may also be bonded to adjacent layers in some embodiments.

[0043] In some embodiments, the manifold layer 205 may be characterized with respect to its length, width, and thickness extending between the length and width of the manifold layer 205 or between opposing surfaces. Similarly, the fluid management layer 210 may be characterized with respect to its length, width, and thickness extending between the length and width of the fluid management layer 210 or between opposing surfaces. The contact layer 215 may also be characterized with respect to its length, width, and thickness extending between the length and width of the contact layer 215 or between opposing surfaces.

[0044] In some embodiments, the thickness of the fluid management layer 210 may be substantially constant over the length and width of the manifold layer 205. The manifold layer 205 may also include a first surface 206 and a second surface 207, the fluid management layer 210 may include a third surface 211 and a fourth surface 212, and the contact layer 215 may include a fifth surface 216 and a sixth surface 217. In some embodiments, one or more of the first surface 206, the second surface 207, the third surface 211, the fourth surface 212, the fifth surface 216, and the sixth surface 217 may generally be characterized as non-planar surfaces. For example, they may be generally recognizable as having one or more undulations and / or deviations from a single geometric plane.

[0045] For example, in some embodiments, one or more of the first surface 206, second surface 207, third surface 211, fourth surface 212, fifth surface 216, and sixth surface 217 may have one or more non-planar surface features. Examples of non-planar surface features include parts of the inner or outer surfaces of a sphere, ellipsoid, torus, cylinder, paraboloid, hyperboloid, cone, prism, pyramid, or tetrahedron. In some embodiments, three of the first surface 206, second surface 207, third surface 211, fourth surface 212, fifth surface 216, and sixth surface 217 may be characterized as substantially convex, and the other three of the first surface 206, second surface 207, third surface 211, fourth surface 212, fifth surface 216, and sixth surface 217 may be characterized as substantially concave. Various surfaces of the tissue interface 120 may be configured to fill tissue areas having depths extending beneath the tissue surface, such as deep wounds, and / or at least partially filling them. In some embodiments, such as those shown in the embodiment of Figure 2, the first surface 206, the third surface 211, and the fifth surface 216 may be characterized as substantially convex, or having mainly convex surface features, and similarly, the second surface 207, the fourth surface 212, and the sixth surface 217 may be characterized as substantially concave, or having mainly concave surface features. For example, both the first surface 206 and the third surface 211 may have at least one outward curvature, and similarly, both the second surface 207 and the fourth surface 212 may have at least one inward curvature. In some embodiments, these curvatures may be substantially constant over the length of the dressing 110, the width of the dressing 110, or both. Additionally or alternatively, these curvatures may vary over the length of the dressing 110, the width of the dressing 110, or both.

[0046] In some embodiments, the curvature exhibited by the first surface 206, the second surface 207, the third surface 211, or the fourth surface 212 may be such that each surface is deviated from the plane by at least about 50% of the combined thickness of the layers of the dressing 110, or about the combined thickness of the layers of the dressing 110, or at least about 125% of the combined thickness of the layers of the dressing 110, or at least about 150% of the combined thickness of the layers of the dressing 110, or at least about 175% of the combined thickness of the layers of the dressing 110, or at least about 200% of the combined thickness of the layers of the dressing 110, or at least about 225% of the combined thickness of the layers of the dressing 110, or at least about 250% of the combined thickness of the layers of the dressing 110, or at least about 275% of the combined thickness of the layers of the dressing 110, or at least about 300% of the combined thickness of the layers of the dressing 110. For example, the curvature exhibited by the first surface 206, the second surface 207, the third surface 211, or the fourth surface 212 may be such that each surface exhibits a change in height between two points on each surface of at least about 50% of the combined thickness of the layers of dressing 110, or about the combined thickness of the layers of dressing 110, or at least about 125% of the combined thickness of the layers of dressing 110, or at least about 150% of the combined thickness of the layers of dressing 110, or at least about 175% of the combined thickness of the layers of dressing 110, or at least about 200% of the combined thickness of the layers of dressing 110, or at least about 225% of the combined thickness of the layers of dressing 110, or at least about 250% of the combined thickness of the layers of dressing 110, or at least about 275% of the total thickness of the layers of dressing 110, or at least about 300% of the combined thickness of the layers of dressing 110.

[0047] In some embodiments, for example, if the tissue site to be treated has a depth that extends below the surface of the tissue, the tissue interface 120 may be configured to allow the convex surface to face the tissue site. For example, in the situation shown in Figure 2, the first surface 206 and the third surface 211 may extend into the tissue site and at least partially fill any voids within the tissue site when the tissue interface 120 is positioned relative to the tissue site.

[0048] The manifold layer 205 may generally be equipped with means for collecting or distributing fluid across the tissue interface 120 under pressure, for example, the manifold layer 205 may be adapted to receive and distribute negative pressure from a source. In some embodiments, the manifold layer 205 may include, or be formed from, a mesh foam having pore size and free volume which may vary depending on the needs of the indicated therapy. For example, a mesh foam with at least 90% free volume may be suitable for many therapeutic applications, and a foam with an average pore size in the range of 400–600 microns (40–50 pores per inch) may be particularly suitable for certain types of therapy. The tensile strength of the manifold layer 205 may also vary depending on the needs of the indicated therapy. The 25% compressive load deflection of the manifold layer 205 may be at least 0.35 pounds / square inch, and the 65% compressive load deflection may be at least 0.43 pounds / square inch. In some embodiments, the tensile strength of the manifold layer 205 may be at least 10 pounds / square inch. The manifold layer 205 may have a tear strength of at least 2.5 pounds / inch. In some embodiments, the manifold layer 205 may be a foam composed of a polyol such as polyester or polyether, an isocyanate such as toluene diisocyanate, and polymerization modifiers such as amines and tin compounds. In some examples, the manifold layer 205 may be a mesh polyurethane foam, as seen in VAC® GRANUFOAM® dressing or VAC® VERAFLO® dressing, both available from Kinetic Concepts, Inc. (San Antonio, Texas).

[0049] Alternatively, in some embodiments, the manifold layer 205 may include a closed-cell foam. For example, in some embodiments, the manifold layer 205 may include an expanded foam, for example, a foam formed from a process including the expansion of a foam precursor material. For example, in some embodiments, the expanded foam may be formed from a process including the extrusion of a polymer material, impregnation of a polymer material with an inert gas at high heat and pressure to form an impregnated polymer material, and expansion of the impregnated polymer material to form an expanded foam material.

[0050] During the extrusion process, the raw polymer material is melted and extruded through a die to form a generally continuous stock material, such as an extruded polymer material. The polymer material may include any suitable polymer, copolymer, or combination thereof, depending on the needs of the indicated treatment. For example, in various embodiments, the polymer material includes crosslinked ethylene-vinyl acetate copolymer, crosslinked polyolefin, such as crosslinked polyethylene or crosslinked ethyl-methyl-acrylate copolymer.

[0051] In some embodiments, the polymer material may have one or more additives or modifiers incorporated in sufficient quantities to impart a desired effect during the extrusion process. For example, in some embodiments, an antimicrobial material may be incorporated into the polymer material during extrusion. A preferred example of an antimicrobial material is a metal such as silver, which may exist in metallic form, ionic form (e.g., silver salt), or both. In some embodiments, silver may exist in combination with one or more additional metals, such as gold, platinum, ferromanganese, copper, zinc, or a combination thereof. In some examples, silver may be incorporated into the polymer material in an amount of about 1% to about 10% by weight of the polymer material. Additionally or alternatively, in some embodiments, a superabsorbent polymer (SAP) may be incorporated into the polymer material during extrusion. Generally, SAPs can absorb and retain large amounts of liquid, especially water, relative to their mass. Many disposable medical products (e.g., canisters and dressings) use SAPs to retain and stabilize or solidify wound fluids. SAPs may be of a type often referred to as "hydrogels," "superabsorbents," or "hydrophilic colloids." For example, SAP can absorb liquids by bonding with water molecules via hydrogen bonds. In some cases, SAP may be incorporated into a polymer material in an amount of about 10% to about 20% by weight of the polymer material.

[0052] During the impregnation process, the polymer material is exposed to an inert gas under high temperature and pressure, allowing the inert gas to permeate the polymer material. The inert gas may include nitrogen gas, for example, at least 90% by weight of nitrogen gas, or at least 95% by weight of nitrogen gas, or at least 99% by weight of nitrogen gas. By manipulating parameters related to the impregnation process, such as temperature, partial pressure of the inert gas, and duration of impregnation, the properties of the impregnated polymer material, and therefore the properties of the resulting expanded foam, can be altered.

[0053] During the expansion process, the impregnated polymer material is pressurized and heated in the presence of reduced pressure, for example, a pressure lower than the pressure used during the impregnation process. In some embodiments, the impregnated polymer material may be expanded in a low-pressure autoclave. Although not bound by theory, the pressure reduction during the expansion process may allow an inert gas to expand, causing the formation of pores or bubbles within the expanded polymer material. By manipulating parameters related to the expansion process, such as temperature, pressure, and expansion duration, the properties of the expanded polymer material, or expanded foam, can be altered.

[0054] In some embodiments, closed-cell foams, such as expanded foams, may contain multiple pores or cells that are characterized by being substantially uninterconnected. In some embodiments, expanded foams may be characterized as elastic in the presence of negative pressure such that they exhibit resistance to compression, for example, relatively high resistance to compression compared to open-cell foams. The resistance to compression exhibited by expanded foams may depend, among other parameters, on the density of the expanded foam, the hardness of the material forming the expanded foam, and the closed-cell nature of the expanded foam. For example, expanded foams may have a density of approximately 0.04 g / cm³ according to ISO 7214:2012. 3 ~about 0.06g / cm 3 , or approximately 0.045 g / cm³ 3 ~Approx. 0.055g / cm 3 , about 0.05g / cm 3 It can be characterized as having a density of . Furthermore, the expanded foam can be characterized as having a Shore hardness on the OO scale of about 40 to 55, or about 42 to about 48, or about 46 according to ISO 868:2003. In some embodiments, the expanded foam can be characterized as exhibiting a compressive stress-strain at 25% compression of about 39 for 25 mm intercellular space according to ISO 7214:2012, and / or a compressive stress-strain at 50% compression of about 100 for 25 mm intercellular space according to ISO 7214:2012.

[0055] In some embodiments, the manifold layer 205 may include a closed-cell crosslinked polyolefin foam, such as one of the AZOTE® series foams available from Zotefoams Plc (London, England). In various non-limiting examples, the manifold layer 205 may be a closed-cell crosslinked polyethylene foam, such as one of the Plastazote® series foams, a closed-cell crosslinked ethylene copolymer foam, such as one of the Evazote® series foams, or a closed-cell crosslinked ethylene copolymer foam, such as one of the Supazote® series foams, all of which are available from Zotefoams Plc (London, England). In certain exemplary embodiments, the manifold layer 205 may be a closed-cell crosslinked ethylene copolymer foam such as Evazote® EV50.

[0056] In some embodiments, the manifold layer 205 may include one or more openings. For example, in some embodiments, the manifold layer 205 may include a plurality of crushable openings that extend at least partially into the thickness from either the first surface 206 or the second surface 207. The crushable openings may generally be configured to exhibit a relatively high degree of deformation in response to negative pressure applied to the manifold layer 205. For example, the crushable openings may be configured to exhibit a relatively high percentage change in cross-sectional area in a plane parallel to either the first surface 206 or the second surface 207. In some embodiments, the crushable openings are effective in causing the manifold layer 205 to exhibit radial crushing, for example, to show deformation of the manifold layer 205 or a portion thereof, thereby causing the manifold layer 205 to show a reduction in at least one dimension of the first surface 206 and / or the second surface 207 with respect to the dimensions (e.g., nominal or relaxation length and / or nominal or relaxation width) when the manifold layer 205 is not subjected to negative pressure. In some embodiments, the radial crushing exhibited by the manifold layer 205 may be determined by various factors, for example, related to the dimensions of the crushable opening.

[0057] Additionally or alternatively, in some embodiments, the manifold layer 205 may comprise a plurality of fluid openings extending through the thickness between the first surface 206 and the second surface 207. Fluid openings generally refer to openings generally configured to exhibit a relatively low degree of deformation in response to negative pressure applied to the manifold layer 205, for example, by exhibiting a relatively low percentage change in a cross-section in a plane parallel to either the first surface 206 or the second surface 207. Generally, fluid openings may be configured to remain open to allow fluid communication between the first surface 206 and the second surface 207. In some embodiments, such as when the manifold layer 205 contains closed-cell foam, the fluid openings may also provide a path for fluid communication between the first surface 206 and the second surface 207; otherwise, the fluid path through the manifold layer 205 may be absent or insufficient.

[0058] The thickness of the manifold layer 205 may also be varied depending on the needs of the prescribed therapy. For example, the thickness of the tissue interface 120 may be reduced to reduce tension on the surrounding tissue. The thickness of the manifold layer 205 can also affect the adaptability of the manifold layer 205. In some embodiments, a thickness of the manifold layer 205 in the range of about 5 to 10 millimeters may be preferred.

[0059] The fluid management layer 210 may include means for controlling or managing the flow of fluid. In some embodiments, the fluid management layer 210 may include or be formed from a liquid-impermeable elastomer material. For example, the fluid management layer 210 may include or be formed from a polymer film. The fluid management layer 210 may also have a smooth or matte surface texture in some embodiments. For some applications, a polished or glossy finish of grade B3 or higher according to the SPI (Plastics Industry Society) standard may be particularly advantageous. In some embodiments, apart from non-planar surface features, variations in surface height may be limited to an acceptable tolerance. For example, the surface of the fluid management layer 210 may have a height deviation limited to 0.2 millimeters per centimeter.

[0060] In some embodiments, the fluid management layer 210 may be hydrophobic. The hydrophobicity of the fluid management layer 210 can vary, but in some embodiments, the contact angle with water may be at least 90 degrees. In some embodiments, the contact angle with water of the fluid management layer 210 may be 150 degrees or less. For example, in some embodiments, the contact angle of the fluid management layer 210 may be in the range of at least 90 degrees to about 120 degrees, or at least 120 degrees to 150 degrees. The water contact angle can be measured using any standard instrument. A manual goniometer may be used to visually estimate the contact angle, but contact angle measuring instruments may often include, among other things, a horizontal stage, a liquid dropper such as a syringe, a camera, and an integrated system with software designed to calculate the contact angle more accurately and precisely. Non-limiting examples of such integrated systems include the FTÅ125, FTÅ200, FTÅ2000, and FTÅ4000 systems, all commercially available from First Ten Angstroms, Inc. (Portsmouth, Virginia), and the DTA25, DTA30, and DTA100 systems, all commercially available from Kruss GmbH (Hamburg, Germany). Unless otherwise specified, the water contact angle herein is measured using deionized distilled water on a horizontal sample surface for droplets, added from a height of 5 cm or less in air at 20–25°C and 20–50% relative humidity. The contact angles reported herein represent the average of 5–9 measurements, with both the highest and lowest measurements discarded. The hydrophobicity of the fluid control layer 210 may be further enhanced by hydrophobic coatings of other materials such as silicone or fluorocarbon during coating with either liquid or plasma.

[0061] The fluid management layer 210 may also be suitable for welding to other layers, including the manifold layer 205. For example, the fluid management layer 210 may be adapted for welding to the polyurethane foam using thermal, radio frequency (RF) welding, or other heat-generating methods such as ultrasonic welding. RF welding may be particularly suitable for higher polarity materials such as polyurethane, polyamide, polyester, and acrylate. A sacrificial polarity interface may be used to facilitate RF welding of lower polarity film materials such as polyethylene.

[0062] The area density of the fluid management layer 210 may vary depending on the indicated therapy or application. In some embodiments, an area density of less than 40 grams / square meter may be preferred, and an area density of about 20-30 grams / square meter may be particularly advantageous for some applications.

[0063] In some embodiments, for example, the fluid management layer 210 may contain or be formed from a hydrophobic polymer such as a polyethylene film. The simple and inert structure of polyethylene can provide a surface that interacts with biological tissues and fluids with little or no interaction, and can provide a surface that promotes free flow and low adhesion of liquids, which can be particularly advantageous in many applications. Films with higher polarity suitable for lamination to polyethylene films include polyamides, copolyesters, ionomers, and acrylics. A tie layer such as ethylene vinyl acetate or modified polyurethane may be used to aid in bonding polyethylene to polar films. Ethyl methyl acrylate (EMA) films can also have hydrophobic and weldable properties suitable for several configurations.

[0064] As shown in the example in Figure 2, the fluid management layer 210 may have one or more fluid limiting sections 220 that can be uniformly or randomly distributed across the fluid management layer 210. The fluid limiting sections 220 may be bidirectional and pressure-responsive. For example, the fluid limiting sections 220 may generally be in a state that is not normally stretched to substantially reduce the flow of liquid and may include elastic passages that can expand in response to a pressure gradient or deformation of the fluid management layer 210. In some embodiments, the fluid limiting sections 220 may include perforations within the fluid management layer 210. Perforations may be formed by removing material from the fluid management layer 210. For example, perforations may be formed by cutting open the fluid management layer 210, and in some embodiments, the edges of the perforations may be deformed. If there is no pressure gradient or deformation of the fluid management layer 210 across the perforations, the passages may be small enough to form a seal or fluid limiting section, which can substantially reduce or prevent the flow of liquid. Additionally or alternatively, one or more of the fluid limiting sections 220 may be elastomer valves, which are normally closed when not deforming to substantially reduce the flow of fluid and can open in response to a pressure gradient or deformation of the fluid management layer 210. The openings in the fluid management layer 210 may be valves suitable for several applications. The openings may also be formed by removing material from the fluid management layer 210, but the amount of material removed and the resulting dimensions of the opening may be an order of magnitude smaller than that of a perforation, and the edges may not be deformed.

[0065] For example, some embodiments of the fluid limiter 220 may include one or more slots or combinations of slots in the fluid management layer 210. In some examples, the fluid limiter 220 may include linear slots having a length of less than 4 millimeters and a width of less than 1 millimeter. The length may be at least 2 millimeters, and in some embodiments, the width may be at least 0.4 millimeters. A length of about 3 millimeters and a width of about 0.8 millimeters may be particularly suitable for many applications. Tolerances of about 0.1 millimeters may also be acceptable. Such dimensions and tolerances can be achieved, for example, by a laser cutter. Slots in such configurations may function as imperfect valves that substantially reduce the flow of liquid when properly closed or stationary. For example, such slots may form a flow limiter without being completely closed or completely sealed. The slots may expand or open significantly in response to a pressure gradient or deformation of the fluid management layer 210 to allow for an increase in liquid flow.

[0066] In some embodiments, the fluid limiting portion 220 may be distributed across the fluid management layer 210 such that when the fluid management layer 210 is positioned relative to the manifold layer 205, the fluid limiting portion 220 is aligned, overlaps, positioned, or otherwise fluid-coupled to openings or channels within the manifold layer 205.

[0067] The optional contact layer 215 may include or include a sealing layer formed from a soft, flexible material suitable for providing fluid sealing to the tissue site. For example, the contact layer 215 may include, but is not limited to, silicone gels, soft silicones, hydrocolloids, hydrogels, polyurethane gels, polyolefin gels, hydrogenated styrene copolymer gels, foamed gels, soft closed-cell foams such as polyurethane and polyolefin coated with adhesives, polyurethane, polyolefin, or hydrogenated styrene copolymers. In some embodiments, the contact layer 215 may have a thickness of about 200 microns (μm) to about 1000 microns (μm). In some embodiments, the contact layer 215 may have a hardness of about 5 Shore 00 to about 80 Shore 00.

[0068] Furthermore, the contact layer 215 may be composed of a hydrophobic or hydrophilic material. In some embodiments, the contact layer 215 can be a hydrophobic coated material. For example, the contact layer 215 can be formed by coating a gapping material, such as a woven mesh, nonwoven mesh, molded mesh, or extruded mesh, with a hydrophobic material. The hydrophobic material for coating can be, for example, soft silicone.

[0069] The contact layer 215 may have a peripheral portion 225 surrounding or around the inner portion 230, and an opening 235 positioned through the peripheral portion 225 and the inner portion 230. In some examples, the inner portion 230 may substantially correspond to the surface area of ​​the manifold layer 205. The contact layer 215 may also have one or more edges 245 that may form part of the peripheral portion 225. The contact layer 215 may have an inner boundary 250 around the inner portion 230, positioned between the inner portion 230 and the peripheral portion 225. The inner boundary 250 may substantially not include the opening 235, as shown in the example in Figure 2. In some examples, as shown in Figure 2, the inner portion 230 may be positioned symmetrically and centrally within the contact layer 215.

[0070] The openings 235 may be formed, for example, by cutting, by applying local RF or ultrasonic energy, or by other suitable techniques for forming openings. The openings 235 may have a uniform distribution pattern or may be randomly distributed in the contact layer 215. The openings 235 in the contact layer 215 may have many shapes, including, for example, circles, squares, stars, ellipses, polygons, slits, complex curves, straight lines, and triangles, or any combination of such shapes.

[0071] Each of the openings 235 may have uniform or similar geometric properties. For example, in some embodiments, each of the openings 235 may be a circular opening having substantially the same diameter. In some embodiments, the diameter of each of the openings 235 can be about 1 mm to about 50 mm. In other embodiments, the diameter of each of the openings 235 can be about 1 mm to about 20 mm.

[0072] In other embodiments, the geometric properties of the opening 235 may vary. For example, the diameter of the opening 235 may vary depending on the location of the opening 235 within the contact layer 215, as shown in Figure 2. In some embodiments, the diameter of the opening 235 in the peripheral portion 225 of the contact layer 215 may be larger than the diameter of the opening 235 in the inner portion 230 of the contact layer 215. For example, in some embodiments, the opening 235 located in the peripheral portion 225 may have a diameter of about 9.8 mm to about 10.2 mm. In some embodiments, the opening 235 located in the inner portion 230 may have a diameter of about 1.8 mm to about 2.2 mm.

[0073] In the example of Figure 2, the dressing 110 may further include an attachment device such as an adhesive 255. The adhesive 255 may be, for example, a medically acceptable pressure-sensitive adhesive that extends around the periphery, part, or all of the cover 125. In some embodiments, for example, the adhesive 255 may include an acrylic adhesive having a coating weight of 25 to 65 grams / square meter (gsm). Additionally or alternatively, in some embodiments, the adhesive 255 may include a silicone-based adhesive. In some embodiments, a thicker adhesive or a combination of adhesives may be applied to improve the seal and reduce leakage. The adhesive 255 may be a layer having substantially the same shape as the periphery 225. In some embodiments, such a layer of adhesive 255 may be continuous or discontinuous. Discontinuities in the adhesive 255 may be provided by openings or holes (not shown) in the adhesive 255. Openings or holes in the adhesive 255 may be formed after application of the adhesive 255, or by coating the adhesive 255 in a pattern on the side of the support layer, for example, the cover 125. In some exemplary embodiments, openings or holes in the adhesive 255 may also be sized to increase the MVTR of the dressing 110.

[0074] As shown in the example in Figure 2, in some embodiments, the release liner 260 may be attached to or positioned adjacent to the contact layer 215, for example, to protect the adhesive 255 before use. The release liner 260 may also provide rigidity, for example, to assist in the utilization of the dressing 110. The release liner 260 may be, for example, cast paper, film, or polyethylene. Furthermore, in some embodiments, the release liner 260 may be a polyester material such as polyethylene terephthalate (PET) or a similar polar semicrystalline polymer. The use of a polar semicrystalline polymer for the release liner 260 can substantially prevent wrinkles or other deformations of the dressing 110. For example, the polar semicrystalline polymer may be highly oriented and resistant to softening, swelling, or other deformations that may occur when in contact with the components of the dressing 110, or when subjected to temperature changes, environmental changes, or sterilization. In some embodiments, the release liner 260 may have a surface texture that can be imprinted on adjacent layers, such as the contact layer 215. Furthermore, a release agent may be placed on the side surface of the release liner 260 configured to contact the contact layer 215. For example, the release agent may be a silicone coating and may have a release agent suitable for facilitating manual removal of the release liner 260 without damaging or deforming the dressing 110. In some embodiments, the release agent may be, for example, fluorocarbon or fluorosilicone. In other embodiments, the release liner 260 may be uncoated or used without a release agent.

[0075] Figure 2 also shows an example of a fluid conduit 265 and a dressing interface 270. As shown in the example in Figure 2, the fluid conduit 265 may be a flexible tube that can be fluidly coupled to the dressing interface 270 at one end. The dressing interface 270 may be an elbow-shaped connector that, as shown in the example in Figure 2, is positioned above the opening 275 of the cover 125 to provide a fluid path between the fluid conduit 265 and the tissue interface 120.

[0076] In some embodiments, the cover 125 may include a seventh surface 226 and an eighth surface 227. As similarly disclosed with respect to the first surface 206, the second surface 207, the third surface 211, the fourth surface 212, the fifth surface 216, and the sixth surface 217, one or both of the seventh surface 226 and the eighth surface 227 may have one or more non-planar surface features, such as a sphere, ellipsoid, torus, cylinder, paraboloid, hyperboloid, cone, prism, pyramidal mid, or tetrahedron. In some embodiments, one of the seventh surface 226 and the eighth surface 227 may be characterized as substantially convex, and the other as concave. In some embodiments, such as those shown in the embodiment of Figure 2, the seventh surface 226 may be characterized as substantially convex, or having mainly convex surface features, and similarly, the eighth surface 227 may be characterized as substantially concave, or having mainly concave surface features.

[0077] In some embodiments, for example, in the example shown in Figure 2, the cover 125 and the contact layer 215 may be sized such that the peripheral portions of the cover 125 and the peripheral portion 225 of the contact layer 215 each extend beyond the outer periphery of the manifold layer 205 and the fluid management layer 210. For example, the cover 125 and the contact layer 215 may have dimensions such that when the cover 125, manifold layer 205, fluid management layer 210, and contact layer 215 are arranged relative to each other, the outer periphery of the cover 125 has substantially the same spread as the edge 245 of the outer periphery 225 of the contact layer 215. In some embodiments, the contact layer 215 and the cover 125 may be bonded together via an adhesive 255 or the like to enclose the manifold layer 205 and the fluid management layer 210, and a portion of the adhesive 255 may be exposed through an opening 235.

[0078] Figure 3 is an assembled diagram of another example of the dressing 110 of Figure 1, showing additional details that may relate to several embodiments in which the tissue interface 120 includes two or more layers. As similarly stated with respect to Figure 2, the tissue interface 120 shown in Figure 3 includes multiple layers, more specifically, a manifold layer 205, a fluid management layer 210, and a contact layer 215. In the embodiment of Figure 3, the cover 125, manifold layer 205, fluid management layer 210, and contact layer 215 may have substantially equal size and shape, for example, so that each of the cover 125, manifold layer 205, fluid management layer 210, and contact layer 215 has the same spread with respect to the contour or periphery when the cover 125, manifold layer 205, fluid management layer 210, and contact layer 215 are stacked and arranged. Furthermore, in the embodiment shown in Figure 3, each of the cover 125, manifold layer 205, fluid management layer 210, and contact layer 215 may be directly attached to the adjacent layer via adhesive or RF welding.

[0079] Figure 4 is a schematic diagram of an example of a fluid management layer 210, showing additional details that may be relevant to several embodiments. As shown in the example of Figure 4, each of the fluid limiting sections 220 may essentially consist of one or more linear slots having a length of about 3 millimeters. Figure 4 further shows an example of a uniform distribution pattern of the fluid limiting sections 220. In the embodiment of Figure 4, the fluid limiting sections 220 have substantially the same extent as the fluid management layer 210 and are distributed across the fluid management layer 210 in a grid of multiple parallel rows and columns, where the slots are also parallel to each other. In some embodiments, as shown in the example of Figure 4, the columns may be spaced about 3 millimeters apart, and each fluid limiting section 220 within a column may be spaced about 3 millimeters apart at its center. Fluid limiting sections 220 in adjacent rows may be aligned or offset. For example, adjacent rows may be offset as shown in Figure 4, so that the fluid limiting sections 220 are aligned in alternating rows and separated by about 6 millimeters. In some embodiments, the spacing of the fluid limiting units 220 may be varied to increase the density of the fluid limiting units 220 according to the requirements of the therapy.

[0080] Figure 5 is a schematic diagram of an exemplary configuration of the opening 235 and shows additional details that may be relevant to several embodiments of the contact layer 215. In some embodiments, the opening 235 shown in Figure 5 may be associated only with the inner portion 230. In the example of Figure 5, the opening 235 is generally circular and has a diameter of about 2 millimeters. Figure 5 also shows an example of a uniform distribution pattern of the opening 235 in the inner portion 230. In the embodiment of Figure 5, the opening 235 is distributed across the inner portion 230 in a grid of parallel rows and columns. Within each row and each column, the openings 235 may be equidistant from each other, as shown in the example of Figure 5. Figure 5 shows one exemplary configuration that may be particularly suitable for many applications, in which the openings 235 are spaced about 6 millimeters apart along each row and each column and spaced with an offset of 3 millimeters.

[0081] Figure 6 is a schematic diagram of an exemplary contact layer 215 of Figure 5 superimposed on the fluid management layer 210 of Figure 4, and shows additional details that may be relevant to several exemplary embodiments of the tissue interface 120. For example, as shown in Figure 6, the fluid limiting portions 220 may be aligned, overlapped, positioned, or otherwise fluidically coupled to the openings 235. In some embodiments, one or more of the fluid limiting portions 220 may be aligned with the openings 235 only in their inner portions 230, or only partially aligned with the openings 235. In the example of Figure 6, the fluid limiting portions 220 are generally configured such that each of the fluid limiting portions 220 aligns with only one of the openings 235. In other examples, one or more of the fluid limiting portions 220 may align with two or more of the openings 235. For example, any one or more of the fluid limiting portions 220 may be perforations or windows extending across two or more of the openings 235. Additionally or alternatively, one or more of the fluid limiting sections 220 do not need to be aligned with any of the openings 235.

[0082] As shown in the example in Figure 6, the openings 235 may be sized to expose a portion of the fluid management layer 210, the fluid limiting portion 220, or both, through the contact layer 215. In some embodiments, each of the openings 235 may be sized to expose two or fewer of the fluid limiting portions 220. In some embodiments, the length of each fluid limiting portion 220 may be substantially less than or equal to the diameter of each opening 235. In some embodiments, the average dimension of the fluid limiting portions 220 is substantially smaller than the average dimension of the openings 235. For example, in some embodiments, the openings 235 may be elliptical, and the length of each fluid limiting portion 220 may be substantially equal to the major or minor axis. However, in some embodiments, the dimensions of the fluid limiting portions 220 may exceed the dimensions of the openings 235, and the size of the openings 235 may limit the effective size of the fluid limiting portions 220 exposed on the lower surface of the dressing 110.

[0083] In some embodiments, one or more components of the dressing 110 may undergo a thermoforming process, for example, one or more of the cover 125, manifold layer 205, fluid management layer 210, and contact layer 215 may undergo thermoforming to impart non-planar surface features to these components. For example, one or more of the non-planar surfaces of the tissue interface 120, for example, one or more of the first surface 206, second surface 207, third surface 211, fourth surface 212, fifth surface 216, sixth surface 217, seventh surface 226, and eighth surface 227 may be formed by a thermoforming process.

[0084] In some embodiments, two or more components of the dressing 110 may be joined together before thermoforming. Additionally or alternatively, in some embodiments, two or more components of the dressing 110 may be thermoformed separately from each other and then joined together after thermoforming. For example, in some embodiments, the cover 125, manifold layer 205, fluid management layer 210, and contact layer 215 may be joined together first and then subjected to thermoforming. Alternatively, in some embodiments, two or more of the cover 125, manifold layer 205, fluid management layer 210, and contact layer 215 may be thermoformed before being joined to adjacent components of the dressing 110.

[0085] In some embodiments, the thermoforming process includes heating the precursor material to a temperature at which the precursor material becomes flexible. In various embodiments, parameters related to heating the precursor material may be selected based on factors including the material being thermoformed. In some embodiments, in the context of thermoforming a manifold layer 205, the temperature associated with the thermoforming process may generally be lower than the temperature associated with a condensation process in which the manifold layer 205 can be compressed.

[0086] Additionally, in some embodiments, the heated precursor material may be fitted into a mold or template, such as a mandrel. Generally, the mold into which the heated precursor material is fitted may be selected based on the desired properties of the resulting components of the microstructure interface 120. For example, the mold may include three-dimensional shapes such as a sphere, ellipsoid, torus, cylinder, paraboloid, hyperboloid, cone, prism, pyramid, tetrahedron, or a part of the inner or outer surface of a combination thereof. The heated precursor material may be fitted by any suitable method. For example, in some embodiments, the heated precursor material may be fitted into the mold or template by vacuum. Additionally, in some embodiments, the heated precursor material may be cooled while being fitted into the mold, during cooling, one or more surface features may be imparted to one or more of the cover 125, manifold layer 205, fluid management layer 210, and contact layer 215.

[0087] In some embodiments, in addition to or instead of imparting one or more surface features to the components of the dressing 110, the thermoforming process may be effective in modifying one or more parameters associated with the dressing 110, the structural interface 120, or one or more of its components, such as the cover 125, manifold layer 205, fluid management layer 210, and contact layer 215. For example, in some embodiments, the dressing 110, one or more components of the dressing 110, or any combination of components of the dressing 110 may be characterized as exhibiting a decrease in tensile strength after and / or as a result of the thermoforming process. For example, the dressing 110, one or more components of the dressing 110, or any combination of components of the dressing 110 may be characterized as exhibiting a decrease in tensile strength compared to an otherwise similar non-thermoformed dressing. An otherwise similar non-thermoformed dressing, except that it has not undergone the thermoforming process, may be identical to the dressing 110 in all material embodiments. In some embodiments, the dressing 110, one or more components of the dressing 110, or any combination of components of the dressing 110 may, as a result of thermoforming or compared to otherwise similar non-thermoformed dressings, exhibit a tensile strength reduction of at least 10%, or at least 15%, or at least 20%, or at least 25%, or at least 30%, or at least 35%, or at least 40%.

[0088] Additionally or alternatively, in some embodiments, the dressing 110, one or more components of the dressing 110, or any combination of components of the dressing 110 may be characterized as exhibiting increased deflection after and / or as a result of the thermoforming process. For example, the dressing 110, one or more components of the dressing 110, or any combination of components of the dressing 110 may be characterized as exhibiting increased deflection compared to an otherwise similar non-thermoformed dressing.

[0089] In addition or alternatively, in some embodiments, the dressing 110, one or more components of the dressing 110, or any combination of components of the dressing 110 may be characterized as exhibiting improved conformity to the tissue site after and / or as a result of the thermoforming process. For example, the dressing 110, one or more components of the dressing 110, or any combination of components of the dressing 110 may be characterized as exhibiting improved conformity to the tissue site compared to an otherwise similar non-thermoformed dressing.

[0090] For example, although not bound by theory, increased flexure and / or improved fit may result from a decrease in the tensile strength of the dressing 110, one or more components of the dressing 110, or any combination of components of the dressing 110. For example, referring to Figure 7, a cross-sectional view of the dressing 110 of Figure 2 positioned relative to a patient's tissue site 704 is shown. The tissue site 704 may extend through, or be accompanied by, surrounding tissue, e.g., the epidermis 706, dermis 708, and subcutaneous tissue 710. Additionally or alternatively, in some embodiments, the tissue site 704 may include a surface portion that is primarily located on the surface of the epidermis 706, such as an incision. The tissue site 704, e.g., a deep wound, may have a depth that extends below the surface of peripheral tissue, e.g., the epidermis 706. As illustrated in Figure 7, once positioned relative to the tissue site 704, the dressing 110 may extend over the tissue site 704 so that the dressing 110 is supported around its periphery by the peripheral tissue. In some embodiments, the application of one or more forces F (e.g., forces into the tissue site 704) to the dressing 110 in the direction of the tissue site 704 may cause tension to be applied to a region 750 of the dressing 110, one or more components of the dressing 110, or any combination of components of the dressing 110. In some embodiments, a decrease in the tensile strength of the dressing 110, one or more components of the dressing 110, or any combination of components of the dressing 110, such as that resulting from a thermoforming process, may cause increased deflection and / or improved conformability in the dressing 110, one or more components of the dressing 110, or any combination of components of the dressing 110.

[0091] In some embodiments, the dressing 110 may be subjected to a thermoforming process in its entirety, for example, so that the entirety of various components of the dressing 110 may be subjected to the thermoforming process. Alternatively, in some embodiments, less than the entire dressing 110 may be subjected to the thermoforming process. For example, in some embodiments, less than the entirety of one or more components of the dressing 110 may be subjected to the thermoforming process. Additionally or alternatively, in some embodiments, the dressing 110 and / or one or more components of the dressing 110 may include various regions that have undergone a thermoforming process of varying degrees, thereby allowing the dressing 110 and / or one or more components of the dressing 110 to exhibit variations in tensile strength, flexure, and / or conformability in their various regions. For example, in some embodiments, the dressing 110 and / or one or more components of the dressing 110 may include one or more thermoforming regions, for example, one or more tension-relaxing regions.

[0092] For example, referring to Figure 8, an exemplary embodiment of the manifold layer 205 is shown. In the embodiment of Figure 8, the manifold layer 205 includes a plurality of tension-relieving regions, for example, a first tension-relieving region 802, a second tension-relieving region 804, and a third tension-relieving region 806. The manifold layer 205 may also include one or more regions that exhibit relatively little modification to the tensile strength, for example, a first low-modification region 801, a second low-modification region 803, and a third low-modification region 805. The tension-relieving regions, in particular the first tension-relieving region 802, the second tension-relieving region 804, and the third tension-relieving region 806, can be formed by subjecting the tension-relieving regions to a thermoforming process, while the low-modification regions are not subjected to a thermoforming process or are subjected to a lesser degree of thermoforming.

[0093] In the example of Figure 8, one or more of the concentrically arranged tension relaxation regions may be arranged around one or more of the low tension relaxation regions. For example, as shown in the embodiment of Figure 8, the first tension relaxation region 802 may be arranged substantially concentrically around the first low-correction region 801. The second low-correction region 803 may be arranged substantially concentrically around the first tension relaxation region 802. The second tension relaxation region 804 may be arranged substantially concentrically around the second low-correction region 803. The third low-correction region 805 may be arranged around the second tension relaxation region 804, and the third tension relaxation region 806 may be arranged substantially concentrically around the third low-correction region 805. The embodiment in Figure 8 illustrates the arrangement of multiple tension-relaxing and low-modification areas within the manifold layer 205, but various other components of the tissue interface 120 or dressing 110 may include similar arrangements of tension-relaxing and low-modification areas.

[0094] Furthermore, referring to Figure 9, for example, another exemplary embodiment of the manifold layer 205 is shown. In the embodiment of Figure 9, the tissue interface 120 includes a helical tension-relaxing region 902 and a low-modification region 901. While the embodiment of Figure 9 illustrates the arrangement of multiple tension-relaxing and low-modification regions within the manifold layer 205, various other components of the tissue interface 120 or dressing 110 may include similar arrangements of tension-relaxing and low-modification regions.

[0095] In some other exemplary embodiments, the tension relief regions may be arranged in any preferred pattern over the length and width of the dressing 110 and / or one or more components of the dressing 110 to yield desired parameters. For example, in some embodiments, the tension relief regions may be arranged in a pattern or randomly. In some embodiments, the tension relief regions may be concentrated in various areas where tension relief is desired, and less concentrated in areas where tension relief is not desired, or desired to a lower degree.

[0096] A system equipped with a dressing 110 can be advantageously used to provide negative pressure therapy to a user. For example, Figure 10 shows an embodiment of a treatment system 100 positioned for treatment of a tissue site 704. Regardless of the positioning of the treatment system 100 or the type of tissue site, the treatment system 100 may provide treatment to, for example, the epidermis 706, dermis 708, and subcutaneous tissue 710. The treatment system 100 may also be used in other tissue sites, without limitation.

[0097] The dressing 110 may be positioned relative to the tissue site 704 such that the inner portion 230 of the contact layer 215 is positioned in or near the tissue site 704, and the peripheral portion 225 of the contact layer 215 is positioned in near the surrounding tissue, such as the epidermis 706, that surrounds the tissue site 704. Furthermore, the opening 235 within the contact layer 215 may be in fluid communication with the tissue site 704 and / or the surrounding tissue.

[0098] The dressing 110 may be positioned relative to the tissue portion 704 such that its convex surfaces, for example, the first surface 206, the third surface 211, and the fifth surface 216, can face the tissue portion 704. For example, the dressing 110 may be positioned relative to the tissue portion 704 such that one or more non-planar surface features extend within the tissue portion 704.

[0099] The cover 125 may cover the contact layer 215 and the tissue portion 704 to provide a fluid seal and a sealing space 1030 between the tissue portion 704 and the cover 125 of the dressing 110. Furthermore, the cover 125 may cover other tissue, such as a portion of the epidermis 706 surrounding the tissue portion 704, to provide a fluid seal between the cover 125 and the tissue portion 704. In some embodiments, a portion of the periphery of the cover 125 may extend beyond the periphery 225 of the contact layer 215 and be in direct contact with the tissue surrounding the tissue portion 704. In other embodiments, the periphery of the cover 125 may be positioned in contact with, for example, the tissue surrounding the tissue portion 704 to provide a sealing space 1030 without the contact layer 215. Thus, the adhesive 255 may also be positioned between at least the periphery of the cover 125 and tissue such as the epidermis 706 surrounding the tissue portion 704. The adhesive 255 may be disposed on the surface of the cover 125, which is fitted to face the tissue portion 704 and the contact layer 215.

[0100] The adhesive 255 may extend through or be pressed through one or more of the openings 235, for example, to contact the epidermis 706 when the dressing 110 is placed against the tissue site 704, and to fix the dressing 110 to the tissue site 704 or the surrounding tissue. For example, the openings 235 may provide sufficient contact of the adhesive 255 to the epidermis 706 to fix the dressing 110 against the tissue site 704. Additionally, the configuration of the openings 235 and the adhesive 255 may allow for the release and repositioning of the dressing 110 against the tissue site 704. In various embodiments, the size and number of the openings 235 may be adjusted to maximize the surface area of ​​the adhesive 255 that is in fluid communication through the openings 235, depending on the specific application or geometric structure of the contact layer 215, for example.

[0101] Alternatively, in some embodiments, such as those disclosed with respect to Figure 3, where all components of the dressing 110 have the same extent relative to the contour or periphery, the mounting device may be positioned around the edge of the cover 125. The mounting device may comprise, for example, a strip of material, such as a film, having sufficient width to extend between the peripheral portion of the cover 125 and the tissue site 704 or the surrounding tissue, to form a sealing space 1030. An adhesive placed on the mounting device may be pressed onto the cover 125 and epidermis 706 around the tissue site to fix the dressing 110 in place and seal the exposed periphery of the tissue interface 120.

[0102] With the dressing 110 positioned and fixed relative to the tissue site 704, the conduit may be connected between the negative pressure source 105 and the dressing 110, and the negative pressure source 105 may be operated to provide negative pressure therapy to the tissue site 704, for example, through the sealing space 1030 and / or the dressing 110. In some embodiments, the application of negative pressure to the sealing space 1030 and / or the dressing 110 may have the effect of drawing the dressing 110 into the tissue site 704, for example, due to the force applied to the dressing 110.

[0103] In some embodiments, the dressing 110 may be advantageously employed in providing negative pressure therapy as a result of, for example, reduced tensile strength, increased flexure, and / or improved fit to the tissue site indicated by the dressing 110. For example, increased flexure and / or improved fit of the dressing 110 may allow the dressing 110 to provide better contact between the tissue site 704 and the tissue site-facing surface of the dressing 110. Improved contact between the dressing 110 and the tissue site 704 may have the effect of inducing microstrain over substantially the entire tissue site 704, thereby allowing cells across the tissue site 704 to experience strain and improving the outcome of negative pressure therapy.

[0104] As shown in several exemplary embodiments, it will be understood by those skilled in the art that the systems, apparatus, and methods described herein are subject to various modifications and alterations within the scope of the appended claims. Furthermore, descriptions of various alternative forms using terms such as “or” do not require mutual exclusivity unless clearly required by context, and the indefinite articles “a” or “an” do not limit the subject to a single example unless clearly required by context. Components may also be combined or separated in various configurations for sale, manufacture, assembly, or use. In some configurations, various components, for example, dressing 110 or container 115, may be separated from other components for manufacture or sale. In other exemplary configurations, controller 130 may also be manufactured, configured, assembled, or sold independently of other components.

[0105] The attached claims describe the novelty and inventive step of the subject matter described above, but the claims may also include additional subject matter not specifically described in detail. For example, certain features, elements, or embodiments may be omitted from the claims if they are not necessary to distinguish the novelty and inventive step from those already known to those skilled in the art. Features, elements, and embodiments described in the context of some embodiments may also be omitted, combined, or replaced by alternative features that serve the same, equivalent, or similar purposes, without departing from the scope of the invention as defined by the attached claims.

Claims

1. 1. A dressing for treating a tissue site using negative pressure, the dressing having, in a relaxed state in which no external forces are applied to the dressing, both a first non-planar surface and a second non-planar surface opposite the first non-planar surface, the dressing comprising: a fluid management layer including a polymer film and a plurality of fluid restriction portions extending through the polymer film and configured to deform; a manifold layer coupled to the fluid management layer.

2. The dressing of claim 1 , wherein the dressing comprises a length, a width, and a thickness, the thickness being substantially uniform.

3. 10. The dressing of claim 1, wherein the first non-planar surface and the second non-planar surface each deviate from plane by at least 50% of a thickness of the dressing.

4. 10. The dressing of claim 1, wherein the first non-planar surface and the second non-planar surface each deviate from plane by at least a thickness of the dressing.

5. 2. The dressing of claim 1, wherein at least one of the first non-planar surface and the second non-planar surface comprises a non-planar surface feature, the non-planar surface feature comprising at least a portion of a surface of a sphere, an ellipsoid, a torus, a cylinder, a paraboloid, a hyperboloid, a cone, a prism, a pyramid, or a tetrahedron.

6. 2. The dressing of claim 1, wherein the dressing is formed by a thermoforming process including heating the fluid management layer and the manifold layer and conforming the fluid management layer and the manifold layer to a mold while heated, and the first non-planar surface and the second non-planar surface are formed as a result of the thermoforming process.

7. 7. The dressing of claim 6, wherein at least a portion of the dressing exhibits at least a 10% loss in tensile strength after the thermoforming process.

8. The dressing of claim 6 , wherein the dressing exhibits improved conformability to the tissue site after the thermoforming process.

9. 2. The dressing of claim 1, wherein the first non-planar surface is a surface of the fluid management layer and comprises a convex surface, and the second non-planar surface is a surface of the manifold layer and comprises a concave surface.

10. 10. The dressing of claim 1, further comprising a polymer layer coupled to the manifold layer opposite the fluid management layer, the second non-planar surface being a surface of the polymer layer and comprising a concave surface.

11. The dressing of claim 10 , wherein the dressing is formed by a thermoforming process that includes heating the fluid management layer, the manifold layer, and the polymer layer.

12. The dressing of claim 1 , wherein at least a portion of the dressing comprises one or more strain relief regions having a reduced tensile strength relative to another portion of the dressing.

13. The dressing of claim 12 , wherein the one or more strain relief areas are thermoformed.

14. 13. The dressing of claim 12, wherein the one or more tension relief regions comprise a non-planar surface feature, the non-planar surface feature comprising at least a portion of a surface of a sphere, an ellipsoid, a torus, a cylinder, a paraboloid, a hyperboloid, a cone, a prism, a pyramid, or a tetrahedron.

15. 13. The dressing of claim 12, wherein the first strain relief region is concentrically disposed about the second strain relief region.

16. 1. A method for forming a dressing for treating a tissue site with negative pressure, the dressing comprising: a fluid management layer including a polymeric film and a plurality of fluid restriction portions extending through the polymeric film and configured to deform; and a manifold layer coupled to the fluid management layer, the method comprising: heating the fluid management layer and the manifold layer; and conforming the fluid management layer and the manifold layer to a mold while being heated; The method provides the dressing with both a first non-planar surface and a second non-planar surface opposite the first non-planar surface when the dressing is in a relaxed state with no external forces applied to the dressing.

17. 1. A system for treating a tissue site, comprising: A dressing according to any one of claims 1 to 16, and a negative pressure source configured to be fluidly coupled to the dressing.

18. 1. A dressing for treating a tissue site using negative pressure, the dressing comprising: a fluid management layer including a polymer film and a plurality of fluid restriction portions extending through the polymer film and configured to deform; a manifold layer coupled to the fluid management layer; A dressing, wherein the dressing is formed by a thermoforming process including heating the fluid management layer and the manifold layer and conforming the fluid management layer and the manifold layer to a mold while heated, and at least a portion of the dressing exhibits a reduction in tensile strength after the thermoforming process.

19. 20. The dressing of claim 18, wherein a first non-planar surface and a second non-planar surface are formed as a result of the thermoforming process.

20. 20. The dressing of claim 19, wherein the first non-planar surface and the second non-planar surface each deviate from plane by at least 50% of a thickness of the dressing.

21. 20. The dressing of claim 19, wherein at least one of the first non-planar surface and the second non-planar surface comprises at least a portion of a surface of a sphere, an ellipsoid, a torus, a cylinder, a paraboloid, a hyperboloid, a cone, a prism, a pyramid, or a tetrahedron.

22. 20. The dressing of claim 19, wherein the first non-planar surface is a surface of the fluid management layer and comprises a convex surface, and the second non-planar surface is a surface of the manifold layer and comprises a concave surface.

23. 20. The dressing of claim 18, wherein the dressing exhibits improved conformability to the tissue site after the thermoforming process.

24. 1. A method for forming a dressing for treating a tissue site with negative pressure, the dressing comprising: a fluid management layer including a polymeric film and a plurality of fluid restriction portions extending through the polymeric film and configured to deform; and a manifold layer coupled to the fluid management layer, the method comprising: heating the fluid management layer and the manifold layer; and conforming the fluid management layer and the manifold layer to a mold while being heated; The method, wherein at least a portion of the dressing exhibits a reduction in tensile strength after the thermoforming process.